E-705

**E-705** is an investigational bifunctional glyco-immunology cancer therapeutic from **Palleon Pharmaceuticals** designed to combine **PD-L1 checkpoint blockade** with **targeted enzymatic desialylation** of tumor and immune cells. The molecule is a heterodimeric biologic comprising one chain of engineered human **sialidase Neu2** fused to an Fc domain and a second chain containing an **anti-PD-L1 antibody**. By binding PD-L1 on tumor and immune cells, E-705 is intended to both inhibit the PD-1/PD-L1 immune checkpoint axis and locally remove immunosuppressive terminal sialic acids from cell-surface sialoglycans, thereby reversing glycan-mediated immune suppression in the tumor microenvironment. Preclinical studies in human PD-L1 transgenic colon carcinoma models showed dose-dependent tumor growth inhibition, altered immune-cell infiltration, and stronger antitumor activity than non-targeted sialidase E-602 or anti-PD-L1 antibody alone. The program appears to be in preclinical research and development for oncology.

Other names

bifunctional PD-L1-targeted sialidasePD-L1-targeted sialidasePD-L-1-targeted sialidasePD-L 1-targeted sialidase